Pan-Amyloid Radiotracer Excels at Early Cardiac Amyloidosis Detection (MedPageToday) - Oct 12, 2026 - ""We've made tremendous advances on the therapeutic side,' Maurer added. In the current era, patients have their pick of the transthyretin (TTR) stabilizers tafamidis (Vyndamax, Vyndaqel) and acoramidis (Attruby) and the gene silencer vutrisiran (Amvuttra). Though eplontersen (Wainua) was recently shown to offer no cardiovascular outcome benefit in the CARDIO-TTRansform trial, other drug candidates are in the pipeline, including the TTR depleter cliramitug....'A really tricky population that we all see very often in clinic is those early patients who have a high suspicion for ATTR [or cardiac amyloidosis] and we just can't find the test or proof that they have it, and we know that these patients need to be treated early in order to get the best [outcomes],' said session discussant Jan Griffin, MD..."
Media quote
|